Prosecution Insights
Last updated: April 19, 2026

C4 Therapeutics Inc.

5 pending office actions

Portfolio Summary

5
Total Pending OAs
1
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18516589 EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS ELENISTE, PIERRE PAUL 1622 Non-Final OA Nov 21, 2023
18289438 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE SHIAO, REI TSANG 1691 Non-Final OA Nov 03, 2023
18385277 GLUTARIMIDES FOR MEDICAL TREATMENT HIRAKIS, SOPHIA P 1623 Final Rejection Oct 30, 2023
17771204 BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER ENGLISH, CONNOR KENNEDY 1625 Non-Final OA Apr 22, 2022
17723199 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS HIRAKIS, SOPHIA P 1623 Non-Final OA Apr 18, 2022

Managing C4 Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month